Benitec Biopharma PE Ratio 2014-2022 | BNTC
Current and historical p/e ratio for Benitec Biopharma (BNTC) from 2014 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Benitec Biopharma PE ratio as of February 03, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Benitec Biopharma PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-02-03 |
0.22 |
|
0.00 |
| 2022-09-30 |
0.37 |
$-119.48 |
0.00 |
| 2022-06-30 |
1.16 |
$-119.63 |
0.00 |
| 2022-03-31 |
2.34 |
$-179.01 |
0.00 |
| 2021-12-31 |
2.62 |
$-343.30 |
0.00 |
| 2021-09-30 |
3.57 |
$-376.57 |
0.00 |
| 2021-06-30 |
4.25 |
$-378.40 |
0.00 |
| 2021-03-31 |
5.17 |
$-318.40 |
0.00 |
| 2020-12-31 |
3.00 |
$-153.71 |
0.00 |
| 2020-09-30 |
6.28 |
$-2.45 |
0.00 |
| 2020-06-30 |
7.91 |
0 |
0.00 |
| 2020-03-31 |
3.93 |
$-3.30 |
0.00 |
| 2019-12-31 |
5.10 |
$-2.10 |
0.00 |
| 2019-09-30 |
7.11 |
$-2.10 |
0.00 |
| 2017-09-30 |
21.70 |
$-2.10 |
0.00 |
| 2016-09-30 |
14.00 |
$1.20 |
11.67 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.006B |
$0.000B |
|
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
|
